NCT07126158View on ClinicalTrials.gov

Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

November 30, 2025

Primary Completion Date

November 30, 2029

Study Completion Date

November 30, 2029

Conditions
Pancreatic AdenocarcinomaCancer of the PancreasPancreas CancerPancreatic Cancer
Interventions
RADIATION

Stereotactic body radiotherapy

MRIdian and Ethos (adaptive radiation platforms)

DRUG

Defactinib

Taken with 30 minutes of a meal

DRUG

Avutometinib

Can be taken without regard to food.

Trial Locations (1)

63110

Washington University School of Medicine, St Louis

All Listed Sponsors
collaborator

Verastem, Inc.

INDUSTRY

collaborator

The Foundation for Barnes-Jewish Hospital

OTHER

lead

Washington University School of Medicine

OTHER

NCT07126158 - Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma | Biotech Hunter | Biotech Hunter